The FDA has accepted a Biologics License Application (BLA) for ropeginterferon alfa-2b (P1101) for use as a treatment for patients with polycythemia vera (PV) in the absence of symptomatic splenomegaly, according to PharmaEssentia Corporation, the manufacturer of the novel pegylated interferon.
FDA Accepts Application for Ropeginterferon Alfa... - MPN Voice
FDA Accepts Application for Ropeginterferon Alfa-2b for Polycythemia Vera
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
4 Replies
•
Thanks for posting. This is good news
What about treatment for Essential Thrombocythemia Jak2+?
Not what you're looking for?
You may also like...
FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera
ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera »...
FDA Rejects Ropeginterferon alfa-2b for Polycythemia Vera
available for patients with polycythemia vera, the FDA has requested additional information. »...
Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
and low-risk polycythemia vera, irrespective of treatment history....
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
with ropeginterferon alfa-2b-njft outweigh the costs for a broad range of patients with PV....
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment
250-350-500 µg of ropeginterferon alfa-2b is well-tolerated and highly efficacious in patients...